Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, Zografos L, Piguet B, Pournaras CJ, Donati G, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM. Schmidt-Erfurth U, et al. Among authors: sickenberg m. Arch Ophthalmol. 1999 Sep;117(9):1177-87. doi: 10.1001/archopht.117.9.1177. Arch Ophthalmol. 1999. PMID: 10496389 Clinical Trial.
Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.
Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA. Blinder KJ, et al. Among authors: sickenberg m. Ophthalmology. 2003 Apr;110(4):667-73. doi: 10.1016/s0161-6420(02)01998-x. Ophthalmology. 2003. PMID: 12689884 Clinical Trial.
Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples.
Schmidt-Erfurth U, Miller J, Sickenberg M, Bunse A, Laqua H, Gragoudas E, Zografos L, Birngruber R, van den Bergh H, Strong A, Manjuris U, Fsadni M, Lane AM, Piguet B, Bressler NM. Schmidt-Erfurth U, et al. Among authors: sickenberg m. Graefes Arch Clin Exp Ophthalmol. 1998 May;236(5):365-74. doi: 10.1007/s004170050092. Graefes Arch Clin Exp Ophthalmol. 1998. PMID: 9602321 Clinical Trial.
Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM, Birngruber R, van den Berg H, Strong A, Manjuris U, Gray T, Fsadni M, Bressler NM, Gragoudas ES. Miller JW, et al. Among authors: sickenberg m. Arch Ophthalmol. 1999 Sep;117(9):1161-73. doi: 10.1001/archopht.117.9.1161. Arch Ophthalmol. 1999. PMID: 10496388 Clinical Trial.
A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes.
Sickenberg M, Schmidt-Erfurth U, Miller JW, Pournaras CJ, Zografos L, Piguet B, Donati G, Laqua H, Barbazetto I, Gragoudas ES, Lane AM, Birngruber R, van den Bergh H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM. Sickenberg M, et al. Arch Ophthalmol. 2000 Mar;118(3):327-36. doi: 10.1001/archopht.118.3.327. Arch Ophthalmol. 2000. PMID: 10721954 Clinical Trial.
Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series.
Saperstein DA, Rosenfeld PJ, Bressler NM, Rosa RH Jr, Sickenberg M, Sternberg P Jr, Aaberg TM Sr, Aaberg TM Jr, Reaves TA; Verteporfin in Ocular Histoplasmosis (VOH) Study Group. Saperstein DA, et al. Among authors: sickenberg m. Ophthalmology. 2002 Aug;109(8):1499-505. doi: 10.1016/s0161-6420(02)01103-x. Ophthalmology. 2002. PMID: 12153802 Clinical Trial.
Improvement after verteporfin therapy.
Anand R, Bressler NM, Bressler SB, Gray TE, Harvey P, Haynes L, Koester JM, Manos KS, Miller JW, Murphy S, Reaves A, Sickenberg M, Singerman LJ, Strong A, Stur M; "Improvement After Verteporfin Therapy" Writting Committee for TAP Study Group. Anand R, et al. Among authors: sickenberg m. Arch Ophthalmol. 2003 Mar;121(3):415-6. doi: 10.1001/archopht.121.3.415. Arch Ophthalmol. 2003. PMID: 12617718 No abstract available.
Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3.
Arnold JJ, Blinder KJ, Bressler NM, Bressler SB, Burdan A, Haynes L, Lim JI, Miller JW, Potter MJ, Reaves A, Rosenfeld PJ, Sickenberg M, Slakter JS, Soubrane G, Strong HA, Stur M; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Arnold JJ, et al. Among authors: sickenberg m. Am J Ophthalmol. 2004 Apr;137(4):683-96. doi: 10.1016/j.ajo.2003.11.059. Am J Ophthalmol. 2004. PMID: 15059708
30 results